Advertisement
Singapore markets close in 45 minutes
  • Straits Times Index

    3,285.98
    -7.15 (-0.22%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,269.04
    +67.77 (+0.39%)
     
  • FTSE 100

    8,075.96
    +35.58 (+0.44%)
     
  • Bitcoin USD

    64,069.40
    -2,747.45 (-4.11%)
     
  • CMC Crypto 200

    1,331.41
    -51.16 (-3.70%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,341.00
    +2.60 (+0.11%)
     
  • Crude Oil

    83.12
    +0.31 (+0.37%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,570.39
    -1.09 (-0.07%)
     
  • Jakarta Composite Index

    7,158.84
    -15.69 (-0.22%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Behind Depomed’s Business Strategy

Behind Depomed’s Business Strategy

Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.